Topics

PubMed Journals Articles About "2019 Sickle Cell Disease Guidelines American Society Hematology" RSS

09:54 EST 24th January 2020 | BioPortfolio

2019 Sickle Cell Disease Guidelines American Society Hematology PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest 2019 Sickle Cell Disease Guidelines American Society Hematology articles that have been published worldwide.

More Information about "2019 Sickle Cell Disease Guidelines American Society Hematology" on BioPortfolio

We have published hundreds of 2019 Sickle Cell Disease Guidelines American Society Hematology news stories on BioPortfolio along with dozens of 2019 Sickle Cell Disease Guidelines American Society Hematology Clinical Trials and PubMed Articles about 2019 Sickle Cell Disease Guidelines American Society Hematology for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of 2019 Sickle Cell Disease Guidelines American Society Hematology Companies in our database. You can also find out about relevant 2019 Sickle Cell Disease Guidelines American Society Hematology Drugs and Medications on this site too.

Showing "2019 sickle cell disease guidelines American Society Hematology" PubMed Articles 1–25 of 63,000+

American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease.

Prevention and management of end-organ disease represent major challenges facing providers of children and adults with sickle cell disease (SCD). Uncertainty and variability in the screening, diagnosis, and management of cardiopulmonary and renal complications in SCD lead to varying outcomes for affected individuals.


2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations.

The American Society of Hematology (ASH) convened 5 guideline panels to develop clinical practice recommendations addressing 5 management areas of highest importance to individuals living with sickle cell disease: pain, cerebrovascular complications, pulmonary and kidney complications, transfusion, and hematopoietic stem cell transplant. Panels were multidisciplinary and consisted of patient representatives, content experts, and methodologists. The Mayo Clinic Evidence-Based Practice Center conducted system...

Rifaximin on intestinally-related pathologic changes in sickle cell disease.


Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866.

S100B has pleiotropic effects on vaso-occlusive manifestations in sickle cell disease.

Inpatient pain management in sickle cell disease.

A novel strategy for management of acute pain associated with sickle cell disease (SCD), referred to as the oral tier approach, is described.

Multicenter Evaluation of HemoTypeSC as a Point-of-Care Sickle Cell Disease Rapid Diagnostic Test for Newborns and Adults Across India.

Sickle cell anemia is the commonest genetic disorder in India, and the frequency of the sickle cell gene is very high in the remote tribal areas where facilities are generally limited. Therefore, a rapid and affordable point-of-care test for sickle cell disease is needed.

Validation of a composite vascular high risk profile for adult patients with sickle cell disease.

Evaluation of Ocular Complications by Using Optical Coherence Tomography in Children With Sickle Cell Disease Eye Findings in Children With Sickle Cell Disease.

The aim of this study was to compare optical coherence tomography (OCT) findings in pediatric patients with sickle cell disease (SCD) and healthy individuals and to investigate associations between these data and the patients' systemic findings.

The increased neopterin content in turkish pediatric patients with sickle cell anemia.

In the present study, the possible activation of cellular immunity in SCD patients was investigated. As immune activation parameters, neopterin concentrations and kynurenine/tryptophan ratio for tryptophan degradation in 35 pediatric patients with sickle cell disease (31 HbSS and 4 HbSß) were determined. Our results have shown that neopterin levels (both urinary and serum) are increased in pediatric patients with sickle cell disease. The increase in neopterin concentration was accompanied by significantly ...

Prevalence of enuresis and its impact in quality of life of patients with sickle cell disease.

Evidence indicates an increase in the prevalence of enuresis in individuals with sickle cell disease. The present study aims to evaluate the prevalence and impact of enuresis on quality of life in individuals with sickle cell disease.

Subperiosteal Orbital Hematoma: Imaging Findings of a Rare Complication of Sickle Cell Disease: Subperiosteal orbital hematoma is a rare entity mainly seen in pediatric patients with sickle cell disease and occurs secondary to local vascular disturbances following facial bone infarction.

Sickle cell disease is the most common hemoglobinopathy. Homozygous patients are prone to vaso-occlusive crises. A 19-year-old male patient with the homozygous sickle cell trait was admitted to the hospital due to a sickle cell crisis. During his admission he developed a left periorbital edema. The diagnosis of a subperiosteal orbital hematoma (SOH) was made by CT and MRI imaging. SOH is a rare complication of a VOC. The clinical course is mostly self-resolving, with some cases reporting the need for surgic...

Treating Sickle Cell Anemia: A New Era Dawns.

The 2019 guidelines from the American Society for Apheresis: what's new?

For over 30 years, the American Society for Apheresis (ASFA) has published practice guidelines on the use of therapeutic apheresis in the Journal of Clinical Apheresis (JCA) Special Issue. These guidelines are periodically reviewed with the addition of new indications, retirement of some former indications and the provision of updated recommendations for current indications based on new published literature. During the last 12 years, updated guidelines have been published every 3 years to provide a reflecti...

Hematopoietic stem cell transplantation and cellular therapy in sickle cell disease: where are we now?

Sickle cell disease (SCD) is a common monogenic disorder that is characterized by an A to T substitution in the β-globin gene that leads to the production of hemoglobin S (HbS). Polymerization of HbS leads to significant morbidity including vaso-occlusion, pain, hemolytic anemia, and end organ damage. Allogeneic hematopoietic cell transplantation (allo-HCT) is the only curative treatment; however, suitable donors are not always readily available. This study reviews the current status of allo-HCT and autolo...

Reducing Health Care Disparities in Sickle Cell Disease: A Review.

Sickle cell disease (SCD) is an inherited blood disorder most common among African American and Hispanic American persons. The disease can cause substantial, long-term, and costly health problems, including infections, stroke, and kidney failure, many of which can reduce life expectancy. Disparities in receiving health care among African Americans and other racial/ethnic minority groups in the United States are well known and directly related to poor outcomes associated with SCD. As an orphan disease-one th...

Association of the Δ Mutant Genotype with Sickle Cell Disease in Egyptian Patients.

Sickle cell disease is considered the most common single base mutation in the world, with >250,000 new patients being discovered each year. It consists of a wide spectrum of clinical presentations and complications. The is the mutant genotype of C-C chemokine receptor 5 (CCR5). It is widely distributed due to several micro organisms that target macrophages in different populations. Theoretically, confers an advantage to sickle cell disease patients. The chronic inflammatory response is the main pathogenes...

Reflections of Healthcare Experiences of African Americans With Sickle Cell Disease or Cancer: A Qualitative Study.

The experiences of African American adult patients before, during, and after acute care utilization are not well characterized for individuals with sickle cell disease (SCD) or cancer.

Pediatric to Adult Transition in Sickle Cell Disease: Survey Results from Young Adult Patients.

We surveyed sickle cell disease (SCD) patients who transitioned from pediatric care at Texas Children's Hematology Center (TCHC) to adult care to determine the characteristics of patients with an adult SCD provider, continuation rates of pre-transition therapies, and patient perceptions of the transition process.

Mechanisms of alloimmunization in sickle cell disease.

Red blood cell (RBC) transfusion is an important treatment for some complications of sickle cell disease (SCD). On the contrary, transfusion may lead to alloimmunization to RBC antigens, with such alloantibodies putting patients at risk for acute or delayed hemolysis, and increasing the difficulty of finding compatible RBCs. Patients with SCD are more susceptible to developing RBC alloantibodies than other multiply transfused patient populations, for reasons that are not completely understood. In this revie...

Prevalence and factors associated with renal dysfunction among children with sickle cell disease attending the sickle cell disease clinic at a tertiary hospital in Northwestern Tanzania.

Little is known on how the interaction between Sickle Cell Disease (SCD) and renal insults caused by other coexisting conditions in Sub Saharan Africa such as urinary schistosomiasis, malnutrition and HIV affect the prevalence of renal dysfunction in children with SCD.

End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings.

To address the global burden of sickle cell disease and the need for novel therapies, the American Society of Hematology partnered with the US Food and Drug Administration to engage the work of 7 panels of clinicians, investigators, and patients to develop consensus recommendations for clinical trial end points. The panels conducted their work through literature reviews, assessment of available evidence, and expert judgment focusing on end points related to patient-reported outcome, pain (non-patient-report...

Highlights in Graft-vs-Host Disease From the 60th American Society of Hematology Annual Meeting.

Highlights of the 2019 Japanese Society of Hypertension Guidelines and perspectives on the management of Asian hypertensive patients.

Unlike other international guidelines but in accord with the earlier Japanese Society of Hypertension (JSH) guidelines, the 2019 JSH guidelines ("JSH 2019") continue to emphasize the importance of out-of-office blood pressure (BP) measurements obtained with a home BP device. Another unique characteristic of JSH 2019 is that it sets clinical questions about the management of hypertension that are based on systematic reviews of updated evidence. JSH 2019 states that individuals with office BP 

Highlights in cutaneous T-cell lymphoma from the 60th American Society of Hematology Annual Meeting.


Quick Search